Vorinostat, also known as suberoylanilide hydroxamic acid (SAHA), effectively overcomes Lenvatinib resistance in HCC by suppressing the PI3K/AKT signaling pathway, revealing that AKT activation contributes to Lenvatinib resistance, while HDAC inhibition restores sensitivity to treatment. This evidence concerns the gene HDAC9 and hepatocellular carcinoma.